(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Vtv Therapeutics's earnings in 2025 is -$18,462,000.On average, 1 Wall Street analyst forecast VTVT's earnings for 2025 to be -$12,662,736, with the lowest VTVT earnings forecast at -$12,662,736, and the highest VTVT earnings forecast at -$12,662,736. On average, 1 Wall Street analyst forecast VTVT's earnings for 2026 to be -$11,386,893, with the lowest VTVT earnings forecast at -$11,386,893, and the highest VTVT earnings forecast at -$11,386,893.
In 2027, VTVT is forecast to generate -$12,567,048 in earnings, with the lowest earnings forecast at -$12,567,048 and the highest earnings forecast at -$12,567,048.